New Data Shows Budget Impact of Fecal Management System in Hospital ICU

Cost Savings Due to Reduction in Time of Nursing Staff to Manage Fecal Incontinence

News provided by

Apr 18, 2010, 08:00 ET

ORLANDO, Fla., April 18 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new study results that demonstrate hospitals could realize substantial savings by substituting Flexi-Seal® FMS for traditional fecal management methods. The cost savings are mainly due to a reduction in time required for nursing staff to manage fecal incontinence.(1) This study was presented at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) in Orlando, Florida.

Fecal incontinence is common in hospital intensive care units (ICU) and presents a major challenge for healthcare professionals due to its association with skin breakdown (2), which may increase the risk of infection. Traditional methods for liquid or semiliquid fecal incontinence management, such as the use of absorbent briefs/pads, skin cleansers, and moisturizers, are only moderately successful in alleviating the consequences of fecal incontinence.

A budget impact model was developed to calculate the annual financial implications of using Flexi-Seal® FMS versus traditional fecal management methods in a hospital ICU. Costs of consumables, nurse and nursing assistant time and of treating fecal incontinence-related complications were considered. The average cost per patient per course of diarrhea was calculated for average-weight and bariatric patients. All figures were collected retrospectively from Carondelet St. Mary's an Ascension Hospital, Tucson, AZ.(1)

Results found the average total fecal management costs per patient, per five-day course of diarrhea, including consumables and nursing time only were $423 for Flexi-Seal® FMS patients and $763 for traditional fecal management patients. The annualized burden of ICU fecal incontinence in this hospital (223 patients) was $169,896 using traditional fecal management methods and $94,224 using Flexi-Seal® FMS. The annual savings from Flexi-Seal® FMS adoption were $75,763 by the hospital.(1)

A chart review found that no patients with Flexi-Seal® FMS developed pressure ulcers related to fecal incontinence. However, the reduction in pressure ulcer incidence may not be attributable to use of Flexi-Seal® FMS. A "SKIN Bundle" program, which increased awareness of skin breakdown, was initiated at the same time. Since the potential effects of Flexi-Seal® FMS and the "SKIN Bundle" program on pressure ulcer incidence cannot be separated, the cost reduction due to reduced incidence of pressure ulcers was not included in the budget impact estimation.

About the Flexi-Seal® FMS family of fecal management systems

Flexi-Seal® FMS, a temporary containment device for patients with acute fecal incontinence, was designed to safely and effectively divert fecal matter, protect patients' wounds from fecal contamination, and reduce the risk of skin breakdown and spread of infection. Flexi-Seal® FMS is indicated for patients with little or no bowel control and liquid or semi-liquid stool, and can be used for up to 29 consecutive days. Key features of Flexi-Seal® FMS include:

A soft, low-pressure balloon designed to aid easy insertion and removal, and minimize the chance of tissue necrosis.
A closed-end collection bag which may help reduce the spread of infection.
An entirely latex-free design.

In February 2010, ConvaTec introduced Flexi-Seal® SIGNAL™ FMS which has been enhanced with key new features, including a unique signal indicator that pops to assist clinicians in determining when the retention balloon of the device is filled to an appropriate volume -- providing confidence that the product is filled for its optimum performance -- thus creating a safe and effective seal for patient protection.

About ConvaTec

ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key business divisions – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support health care professionals from the hospital to the community health setting. From its headquarters in Skillman, New Jersey, the company oversees more than 8,000 employees in over 90 countries serving consumers and their health care professionals on six continents. For more information, please visit www.convatec.com.

™/® indicates trademarks of ConvaTec Inc.
© 2010 ConvaTec Inc.	AP-00-9530-US

(1) Popovich-Durnal A, Kommala D, Chen Y. Budget Impact of Adopting a Fecal Management System in a Hospital Intensive Care Unit: A Single Center Experience. Poster presented at: 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society Meeting; April 17-20, 2010; Orlando, Florida.

(2) Junkin J, Selekof JL. Prevalence of incontinence and associated skin injury in the acute care inpatient. J Wound Ostomy Nurs. 2007;34(3):260-269.